Zwj Investment Counsel 13F: Adds $1.8M to JNJ Stake

Zwj Investment Counsel expanded its footprint in Johnson & Johnson NYSE:JNJ during the period, raising its stake in the healthcare heavyweight by 2.9%. Institutional 13F filings submitted to the U.S. Securities and Exchange Commission show that the firm added 6,670 shares to its portfolio, bringing its total ownership to 231,462 shares. Based on the spot price around the filing date, that stake carried a market value of approximately $61.3 million. Because these disclosures look backward at holdings from the close of the reporting period, the figures reflect portfolio adjustments made at that time and may not represent the firm's current exact share count today.

What Changed in Zwj Investment Counsel's Johnson & Johnson Position

Prior to the adjustment, Zwj Investment Counsel held 224,792 shares of the drug manufacturer. The addition of 6,670 shares marked a 3.0% increase for the position. The updated total of 231,462 shares gives the firm a sizable allocation in the healthcare sector, aligning with steady institutional interest in large-cap pharmaceutical names.

Other Institutional Activity in Johnson & Johnson

Other major institutional managers also tweaked their holdings in the healthcare leader during the quarter. Blackrock Inc. reduced its position by 1,280,271 shares, ending the period with 212,098,264 shares valued at about $54.2 billion. Vanguard Capital Management LLC grew its holdings by 626,400 shares, ending with 157,226,374 shares worth about $40.1 billion. State Street Corporation lifted its stake by 293,661 shares to hold 133,776,025 shares valued at roughly $34.2 billion. Vanguard Portfolio Management LLC grew its holdings by 857,431 shares, ending with 64,370,816 shares worth about $16.4 billion. Finally, Geode Capital Management, LLC trimmed its position by 76,912 shares, wrapping up the period with 59,086,417 shares valued at approximately $15.1 billion.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson shares trade around $255.31, sitting comfortably between the 52-week low of $184.66 and the 52-week high of $281.07. The stock tracks near its 50-day moving average of $265.26 and well above its 200-day moving average of $243.87. The company commands a market capitalization of roughly $610.4 billion with a forward P/E ratio of 21.6.

Recent Earnings

Johnson & Johnson generated annual revenues of $99.3 billion with a revenue growth rate of 5.9%. The company posted earnings per share of $6.59 alongside a net profit margin of 16.2% and a return on equity reflecting stable profitability across its Innovative Medicine and MedTech segments. The company's next quarterly earnings report is scheduled for release on January 26, 2027.

Dividend

Johnson & Johnson maintains an annual dividend yield of 2.1% supported by a payout ratio of 60.7%, returning steady cash to shareholders as part of its capital allocation strategy.

Insider Buying and Selling at Johnson & Johnson

Company insiders executed several transactions during recent months. Officer Schmid Timothy disposed of 33,597 shares on September 2, 2026, at an average price of $274.74 for a total value of $9.2 million. Officer Jennifer L. Taubert sold 15,000 shares on August 17, 2026, at $263.36 per share, totaling $4.0 million. Chief Executive Officer Joaquin Boix Duato parted with 123,291 shares on August 13, 2026, valued at $32.2 million. Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, valued at $4.1 million.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on the stock following recent reports. On October 16, 2026, Wells Fargo maintained an Overweight rating and raised its price target to $287.00 from $275.00. Morgan Stanley maintained an Overweight rating with a price target of $292.00 on October 15, 2026. Leerink Partners kept an Outperform rating on October 14, 2026, lowering its target slightly to $272.00. On the same day, Wells Fargo maintained an Overweight rating with a target of $275.00, while RBC Capital maintained an Outperform rating with a price target of $280.00. Overall, the stock carries a consensus buy recommendation from 22 analysts, with a mean price target of $279.41.

About Johnson & Johnson

Headquartered in New Brunswick, New Jersey, Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide. The enterprise operates through two primary divisions, Innovative Medicine and MedTech, delivering advanced therapeutics and medical devices that serve patients globally. Institutional tracking of JNJ stock remains a barometer for broader healthcare sector sentiment.

Bottom Line

Investors tracking Zwj Investment Counsel's positioning will want to monitor upcoming institutional 13F disclosures and the company's scheduled earnings report in January 2027. Filings reflect historical snapshots and do not guarantee current or future allocations.